MARCHESELLI, Raffaella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.135
EU - Europa 2.901
AS - Asia 2.496
SA - Sud America 338
AF - Africa 80
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 5
Totale 11.970
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.014
GB - Regno Unito 1.305
SG - Singapore 746
CN - Cina 680
IT - Italia 425
HK - Hong Kong 305
VN - Vietnam 251
DE - Germania 250
BR - Brasile 237
SE - Svezia 223
FR - Francia 147
FI - Finlandia 127
RU - Federazione Russa 112
UA - Ucraina 108
BD - Bangladesh 94
IN - India 76
TR - Turchia 74
CA - Canada 66
KR - Corea 53
BG - Bulgaria 43
ID - Indonesia 40
MA - Marocco 40
AR - Argentina 39
IQ - Iraq 30
MX - Messico 24
BE - Belgio 20
ES - Italia 19
NL - Olanda 19
PL - Polonia 19
EC - Ecuador 16
PK - Pakistan 16
AE - Emirati Arabi Uniti 15
CO - Colombia 14
IE - Irlanda 14
ZA - Sudafrica 14
AU - Australia 13
CH - Svizzera 13
CZ - Repubblica Ceca 13
JP - Giappone 12
MY - Malesia 11
SA - Arabia Saudita 11
UZ - Uzbekistan 10
AT - Austria 9
IR - Iran 9
VE - Venezuela 9
AZ - Azerbaigian 8
CL - Cile 8
LT - Lituania 8
PH - Filippine 8
HU - Ungheria 7
CR - Costa Rica 6
DO - Repubblica Dominicana 6
JO - Giordania 6
PY - Paraguay 6
BZ - Belize 5
JM - Giamaica 5
KE - Kenya 5
KG - Kirghizistan 5
KZ - Kazakistan 5
DK - Danimarca 4
TH - Thailandia 4
TN - Tunisia 4
BO - Bolivia 3
EG - Egitto 3
EU - Europa 3
GP - Guadalupe 3
LB - Libano 3
NO - Norvegia 3
NP - Nepal 3
PS - Palestinian Territory 3
UY - Uruguay 3
BH - Bahrain 2
CY - Cipro 2
ET - Etiopia 2
IL - Israele 2
KH - Cambogia 2
MU - Mauritius 2
NZ - Nuova Zelanda 2
PA - Panama 2
PE - Perù 2
PT - Portogallo 2
QA - Qatar 2
RO - Romania 2
RS - Serbia 2
TZ - Tanzania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AD - Andorra 1
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BB - Barbados 1
BF - Burkina Faso 1
DZ - Algeria 1
EE - Estonia 1
GA - Gabon 1
GE - Georgia 1
GH - Ghana 1
GR - Grecia 1
GY - Guiana 1
HN - Honduras 1
Totale 11.955
Salva come PNG Salva come JPEG
Città #
Southend 1.070
Ashburn 665
Fairfield 592
Santa Clara 528
Singapore 488
Woodbridge 458
Hong Kong 298
Houston 278
Chandler 269
Seattle 247
Wilmington 222
Ann Arbor 206
Cambridge 205
Jacksonville 203
San Jose 195
Beijing 192
Dearborn 163
Nyköping 162
Hefei 138
New York 117
London 114
Modena 97
Council Bluffs 94
Los Angeles 82
Chicago 80
Helsinki 78
Ho Chi Minh City 70
Frankfurt am Main 66
The Dalles 62
San Diego 57
Milan 54
Hanoi 50
Seoul 50
Shanghai 44
Princeton 42
Sofia 42
Munich 39
Eugene 38
Buffalo 36
Moscow 36
Salt Lake City 35
Casablanca 32
Lauterbourg 32
Izmir 30
Bremen 26
Bologna 25
Jakarta 24
Columbus 22
Dallas 22
Montreal 21
São Paulo 21
Brussels 19
Elk Grove Village 19
Rome 19
Da Nang 17
Redwood City 17
Warsaw 17
Falls Church 16
Orem 16
Phoenix 16
Toronto 15
Turku 15
Dublin 14
New Delhi 14
Boardman 13
Brooklyn 13
Denver 13
Des Moines 13
Nanjing 13
Fremont 12
Guangzhou 12
Manchester 12
Tampa 12
Baghdad 11
Poplar 11
Tokyo 11
Buenos Aires 10
Chennai 10
Dong Ket 10
Paris 10
Boston 9
Kunming 9
Norwalk 9
Ottawa 9
Rho 9
Gurugram 8
Indiana 8
San Giuliano Milanese 8
San Mateo 8
Sterling 8
Stockholm 8
Tashkent 8
Baku 7
Carpi 7
Dhaka 7
Johannesburg 7
Lahore 7
Nuremberg 7
Quito 7
Turin 7
Totale 8.774
Salva come PNG Salva come JPEG
Nome #
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 621
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 523
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 455
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 406
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 387
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 362
Body composition and inflammation impact in non-small cell lung cancer patients treated by first-line immunotherapy 351
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 342
A concise review of lenalidomide therapy for follicular lymphoma 341
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 332
The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments 321
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 316
Phase II Study of Velcade (R) Plus Mabthera (R) In Relapsed Follicular Lymphomas. 314
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 311
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 307
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 304
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 303
Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw. 299
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma 291
Incidence and outcome of Myelodysplastic Syndromes in province of Modena 288
BISPHOSPHONATES (BP) RELATED OSTEONECROSIS OF THE JAW (ONJ): A LONG TERM FOLLOW UP (FU) OF A SERIES OF 35 CASES OBSERVED BY GISL 286
INCIDENCE AND SURVIVAL OF MYELOID MALIGNANCIES IN 1102 PATIENTS IN PROVINCE OF MODENA, NORTHERN ITALY 282
A RANDOMIZED PHASE II STUDY (GISL - MM03 TRIAL) WITH ORAL MELPHALAN+ PREDNISONE (MP) VERSUS MELPHALAN, + PREDNISONE + THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA 281
Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts 276
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients 275
Efficacy Controls and Long-Term Follow-Up of Patients (Pts) Treated with FC Plus Rituximab for Relapsed Follicular NHL. Session Type: Publication Only 273
Incidence and outcome of chronic myeloproliferative disorders: A population-based study from a cancer registry in northern Italy 269
: Late toxicity and quality of life (QOL) after treatment for Hodgkin disease (HD): A Gruppo Italiano Studio Linfomi (GISL) cohort study on 223 patients 264
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant 264
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 250
Secondary malignancies after treatment of aggressive non-Hodgkin lymphoma: A GISL cohort study on 1259 patients 249
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 242
Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL. 236
VALIDATION OF ABSOLUTE LYMPHOCYTE COUNT / REVISED IPI (ALC/R-IPI) SCORE MODEL, AS A PROGNOSTIC INDEX FOR DIFFUSE LARGE-B-CELL LYMPHOMA IN RITUXIMAB ERA 235
Bisphosphonates-associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time 230
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 224
Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting 210
Treatment of patients with recurrent follicular lymphoma with rituximab in combination with fludarabine and cyclophosphamide 183
Rituximab in combination with chemotherapy has improved survival of patients with follicular lymphoma 172
Epidemiologia degli infortuni lavorativi in minori: risultati di una indagine condotta nella città di Modena nel periodo gennaio-giugno 2000. 169
Totale 12.044
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.456
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.456
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202178 0 0 0 0 0 0 0 0 0 0 0 78
2021/2022874 30 86 80 49 24 74 49 50 107 61 156 108
2022/2023854 92 111 60 78 98 118 26 87 93 10 55 26
2023/2024683 24 26 49 63 145 59 146 48 17 16 35 55
2024/20251.761 66 19 42 121 373 276 124 108 195 56 140 241
2025/20263.507 241 144 204 385 586 222 446 171 369 368 212 159
Totale 12.044